To ensure the continuity of biomedical research into rare genetic diseases, we have established two institutes in Italy that have become known and valued worldwide.
542
professional resources
15,2 millions
2024 investment on Tigem
15,6 millions
2024 investment on SR-Tiget
Headed by Luigi Naldini, SR-Tiget is a world leader for gene therapy: the therapy for the treatment of ADA-SCID is one of the first examples of effective gene therapy in the world.
Headed by Alberto Auricchio, Tigem is an institute where researchers could focus on studying the mechanisms underlying genetic diseases and on developing innovative therapeutic strategies.
